Evaluation of effectiveness of complex treatment of patients with chronic pancreatitis with metabolic syndrome
Currently, the metabolic syndrome is considered as a factor in the development of chronic pancreatitis, and type 2 diabetes mellitus, along with insulin resistance, abdominal-visceral obesity, hyper- and dyslipidemia, arterial hypertension and activation of nonspecific generalized inflammation are considered metabolic syndrome manifestations. The results of the evaluation of the effectiveness of complex treatment of patients with chronic pancreatitis with metabolic syndrome are presented in this article.
The results of the present study demonstrate the effectiveness of the combined use of substitution enzyme therapy and α-lipoic acid due to a positive effect on the adipocytokine status, carbohydrate, lipid metabolism and indices of the functional state of the pancreas.
2. Conti Bellocchi, M. C., De Pretis, N., Amodio, A., Zerbi, A., Frulloni, L. (2018). Chronic pancreatitis: new definition and perspectives. Recenti Prog Med.,109 (1), 69-72.
3. Duggan, S. N., Ní Chonchubhair, H. M., Lawal, O., O’Connor, D. B., Conlon, K. C. (2016). Chronic pancreatitis: A diagnostic dilemma. World J Gastroenterol., 22 (7), 2304-2313.
4. Löhr, J. M., Dominguez–Munoz, E., Rosendahl, J., Besselink, M., Mayerle, J., Lerch, M. M. ... Bruno, M. (2017). United European Gastroenterology evidence–based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United European Gastroenterol J., 5 (2), 153-199.
5. Rajesh, G., Kumar, H., Menon, S., Balakrishnan, V. (2012). Pancreatitis in the setting of the metabolic syndrome. Indian J Gastroenterol., 31 (2), 79-82.